extent to which the targeted populations have been reached; (2) Document how well the project is progressing in meeting goals/objectives set forth by CDC (e.g. who delivered what to whom, how many, where, when, and how well), as well as performance indicators related to testing, counseling and linkage to care; (3) Highlight opportunities for local program collaboration and service integration (PCSI) to prevent hepatitis; (4) Fulfill data collection and reporting requirements outlined in the cooperative agreements.

The data will enable CDC to be accountable for the funding it provides, the populations that are served, the services being provided, and for the strategies and practices effectiveness in implementing HEPTLC. The data will also enable CDC to be accountable to the administration, Congress, or other stakeholders for the proper use of public money or provide transparency for the programs it funds.

Respondents will be testing sites at multiple settings, including health departments, community based organizations (CBOs), community health centers (CHCs), persons who inject drugs (PWIDs) treatment centers, and other settings, e.g. HIV or STD clinics, Federally Qualified Health Centers (FQHCs). They will routinely collect, enter, and report information about the test site, client demographics and behaviors, testing results and linkage to care follow up information within the web-based HEPTLC system. CDC anticipates that routine information collection will begin once OMB approval is received and will be carried out through the project period September 2012–September 2013.

There are no costs to respondents other than their time. The total estimated annual burden hours are 6000.

### ESTIMATED ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Type of respondents</th>
<th>Form name</th>
<th>Number of respondents</th>
<th>Responses per respondent</th>
<th>Average burden per response (in hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBV—CBOs/Health Jurisdictions</td>
<td>HEPTLC Data Variables &amp; Values (test-level monthly reporting)</td>
<td>40</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>HBV—CBOs/Health Jurisdictions</td>
<td>HEPTLC Template (program-level reporting/quarterly)</td>
<td>40</td>
<td>4</td>
<td>1.5</td>
</tr>
<tr>
<td>HCV—multiple sites (IDU, CHCs, Others, ECHO)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCV—multiple sites (IDU, CHCs, Others, ECHO)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Ron A. Otten,
Director, Office of Scientific Integrity (OSI), Office of the Associate Director for Science (OADIS), Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2012–26498 Filed 10–26–12; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Subcommittee for Dose Reconstruction Reviews (SDRR), Advisory Board on Radiation and Worker Health (ABRWH or the Advisory Board), National Institute for Occupational Safety and Health (NIOSH)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting for the aforementioned subcommittee:

**Time and Date:** 8:30 a.m.–5:00 p.m. Eastern Time, November 27, 2012.

**Place:** Cincinnati Airport Marriott, 2395 Progress Drive, Hebron, Kentucky 41018. Telephone (859) 334–4611, Fax (859) 334–4619.

**Status:** Open to the public, but without an oral public comment period. To access by conference call dial the following information 1 (866) 659–0537, Participant Pass Code: 9533701.

**Background:** The Advisory Board was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program.

**Purpose:** The Advisory Board is charged with (a) providing advice to the Secretary, HHS, on the development of probability of causation guidelines that have been promulgated by the Department of Health and Human Services (HHS) as a final rule; (b) advising on methods of dose reconstruction, which have also been promulgated by HHS as a final rule; (c) advising on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program; and (d) advising on petitions to add classes of workers to the Special Exposure Cohort (SEC).

In December 2000, the President delegated responsibility for funding, staffing, and operating the Advisory Board to HHS, which subsequently delegated this authority to CDC. NIOSH implements this responsibility for CDC. The charter was issued on August 3, 2001, renewed at appropriate intervals, and will expire on August 3, 2013.

**Matters To Be Discussed:** The agenda for the Subcommittee meeting includes:

- Reconsidering the Board’s dose reconstruction case review process; dose reconstruction program quality management and assurance activities, including: Current findings from NIOSH internal dose reconstruction blind reviews, presentation of the test plan for validating dose reconstruction tools, presentation of the evolution of peer-review procedures, presentation of statistics summarizing errors detected and/or corrected through current peer-review procedures; and discussion of dose reconstruction cases under review (sets 8–9, Rocky Flats Plant cases from sets 10–13, and two blind dose reconstruction cases).

The agenda is subject to change as priorities dictate.

In the event an individual cannot attend, written comments may be submitted. Any written comments received will be provided at the meeting and should be submitted to the contact person below well in advance of the meeting.

**Contact Person for More Information:** Theodore Katz, Executive Secretary, NIOSH, CDC, 1600 Clifton Road, Mailstop E–20, Atlanta, Georgia 30333. Telephone (513)
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Council for the Elimination of Tuberculosis (ACET)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

**Times and Dates:** 8:30 a.m.–5:30 p.m., December 4, 2012; 8:30 a.m.–2:30 p.m., December 5, 2012.

**Place:** CDC, Corporate Square, 1800 Corporate Boulevard, Building 8, 1st Floor Conference Room, Atlanta, Georgia 30329.

**Telephone:** (404) 639–8317.

**Status:** Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

**Purpose:** This council advises and makes recommendations to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the elimination of tuberculosis. Specifically, the Council makes recommendations regarding policies, strategies, objectives, and priorities; addresses the development and application of new technologies; and reviews the extent to which progress has been made toward eliminating tuberculosis.

**Matters To Be Discussed:** Agenda items include the following topics: (1) CDC’s efforts on global tuberculosis control; (2) The epidemiology of TB–HIV in the United States; (3) Post-deployment tuberculosis in the United States military; (4) ACET workgroups activities updates; and (5) other tuberculosis-related issues.

**Agenda items are subject to change as priorities dictate.**

**Contact Person for More Information:** Margie Scott-Cobb, CDC, 1600 Clifton Road NE, MS E–07, Atlanta, Georgia 30333. Telephone: (404) 639–8317.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Dated:** October 22, 2012.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Survey on the Occurrence of Foodborne Illness Risk Factors in Selected Retail and Foodservice Facility Types (2013–2022)—(OMB Control Number 0910–NEW)

**I. Background**

In 1998, the U.S. Food and Drug Administration’s National Retail Food Team initiated a 10-year voluntary survey to measure trends in the occurrence of foodborne illness risk factors—preparation practices and employee behaviors most commonly reported to the Centers for Disease Control and Prevention (CDC) as contributing factors to foodborne illness outbreaks at the retail level. Specifically, the survey included data collection inspections of various types of retail and foodservice establishments at 5-year intervals (1998, 2003, and 2008) in order to observe and document trends in the occurrence of the following foodborne illness risk factors:

- Food from Unsafe Sources.
- Poor Personal Hygiene.
- Inadequate Cooking.
- Improper Holding/Time and Temperature.
- Contaminated Equipment/Protection from Contamination.

FDA developed reports summarizing the findings for each of the three data collection periods (1998, 2003, and 2008) (Refs. 1 to 3). Data from all three data collection periods were analyzed to detect trends in improvement or regression over time and to determine whether progress had been made toward the goal of reducing the occurrence of foodborne illness risk factors in selected retail and foodservice facility types (Ref. 4).

The research obtained from these studies provides FDA a solid foundation for developing a national retail food program model that can be used by Federal, State, local, and tribal agencies to:

- Identify essential food safety program performance measurements;
- Assess strengths and gaps in the design, structure, and delivery of program services;
- Establish program priorities and intervention strategies focused on reducing the occurrence of foodborne illness risk factors; and
- Create a mechanism that justifies program resources and allocates them to program areas that will provide the most significant public health benefits.

Using this 10-year survey as a foundation, FDA is proposing to conduct a new voluntary survey encompassing annual data collections over a 10-year period. The survey will